Vistagen obtains new patents for PH80 migraine therapy

Vistagen has announced a significant expansion of its global intellectual property portfolio with the acquisition of several new patents for its innovative PH80 nasal spray. This neuroactive pherine nasal spray is specifically developed to treat migraines, adding to the company's diverse array of treatment options for neurological and psychiatric disorders.

Previously, Vistagen has successfully obtained patents for PH80 in the United States and from the European Patent Office. The newly acquired patents extend the protection of PH80 until at least 2040, contingent upon possible extensions. These new patents were granted by intellectual property authorities in Australia, Hong Kong, Japan, and Mexico.

In Australia, Vistagen's PH80 was issued a Notice of Allowance. Meanwhile, the Hong Kong Intellectual Property Department granted it Patent No. 40068177, the Japan Patent Office issued Patent No. 7476229, and the Mexican Institute of Industrial Property granted a notice of allowance.

PH80 is noteworthy for its unique mechanism of action, targeting neurocircuitry without the need for systemic absorption or direct neuronal activity in the brain. The nasal spray is being developed as a hormone-free treatment option for various women's health issues, including vasomotor symptoms associated with menopause, premenstrual dysphoric disorder, dysmenorrhea, and migraines.

Pherines, a new class of compounds to which PH80 belongs, are designed to treat psychiatric and neurological disorders through mechanisms focused on neurocircuitry. Vistagen, a biopharmaceutical company specializing in neuroscience, is committed to the development and commercialization of such innovative therapies. The company's pherine drug candidates have shown favorable safety profiles across all completed studies.

In addition to the advancements with PH80, Vistagen made strides in other areas of neurological treatment. In 2023, the company received a Notice of Allowance from the Canadian Intellectual Property Office for a patent related to the use of AV-101 in treating patients with Parkinson’s disease. AV-101 is particularly effective in reducing dyskinesia, the sudden and uncontrolled movements caused by the Parkinson’s medication levodopa.

Vistagen's ongoing efforts in expanding its intellectual property portfolio and developing unique treatment options underscore its commitment to addressing unmet needs in the field of psychiatric and neurological disorders. The company's progress with PH80 and other drug candidates highlights its dedication to innovation and improving patient outcomes in these challenging medical areas.